Prevalence and Antigen Specificity of Anti-Histone Antibodies in Patients with Polymyositis/Dermatomyositis  by Kubo, Masahide et al.
Prevalence and Antigen Specificity of Anti-Histone Antibodies
in Patients with Polymyositis/Dermatomyositis
Masahide Kubo, Hironobu Ihn, Norihito Yazawa, Shinichi Sato,* Kanako Kikuchi, and Kunihiko Tamaki
Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan; *Department of Dermatology, Faculty of Medicine, Kanazawa
University, Kanazawa, Japan
Anti-histone antibodies have been detected in the sera
of patients with various autoimmune diseases. The
existence of anti-histone antibodies in patients with
polymyositis/dermatomyositis, however, has not been
reported. We found anti-histone antibodies in eight
(17%) of 46 sera from patients with polymyositis/
dermatomyositis by an enzyme-linked immunosorb-
ent assay. One serum was positive for both IgG anti-
histone antibodies and IgM anti-histone antibodies. Six
sera were positive only for IgG anti-histone antibodies.
One serum was positive only for IgM anti-histone
antibodies. An indirect immunofluorescence analysis
using HEp-2 cells as the substrate showed that all
sera positive for anti-histone antibodies produced
homogeneous nuclear fluorescence. This immuno-
fluorescence pattern disappeared after absorption of
anti-histone activity with total histones. An immuno-
blotting analysis demonstrated that the anti-histone
antibodies were predominantly directed against
Polymyositis/dermatomyositis (PM/DM) is an uncom-mon inflammatory condition characterized by subacuteskeletal muscle involvement, and by typical cutaneouslesions in DM. PM/DM shares many clinical andlaboratory features with other collagen diseases. Clinic-
ally, DM often also shows malar rash or subungual erythema, and
PM/DM sometimes shows lung fibrosis. In laboratory findings, the
existence of autoantibodies including Jo-1 antibody and anti-nuclear
antibodies (ANA) is sometimes seen in PM/DM (Maddison, 1996).
Autoantibodies to aminoacyl transfer ribonucleic acid (tRNA)
synthetase have been reported as specific antibodies to PM/DM
(Maddison, 1996). Anti-tRNAhis (Jo-1), tRNAthr (PL-7), tRNAala
(PL-12), tRNAgly (EJ), and tRNAile (OJ) antibodies are presently
known. Clinically, patients with anti-tRNA synthetase antibodies
were called as anti-synthetase syndrome, and they are reported to
have lung fibrosis more often than patients without these antibodies
(Love et al, 1991; Friedman et al, 1996). Anti-Jo-1 antibodies are
more prevalent in PM than in DM (Targoff and Reichlin, 1987),
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histone H1 in all seven sera with IgG anti-histone
antibodies. Weak reactivity with H2B and H4 were
also found in three sera from the patients with poly-
myositis/dermatomyositis. Sera from two patients
with polymyositis/dermatomyositis displayed anti-
H2A and H3 activity. One of the two sera showed IgM
anti-histone antibodies in the enzyme-linked immuno-
sorbent assay reacted with H1, H2A, H2B, H3, and
H4, whereas the other serum reacted with no fractions
of total histones. The activity of anti-histone antibodies
disappeared in immunoblotting after absorption with
total histones. All of the patients with anti-histone
antibodies were free from lung fibrosis or internal
malignancies. Thus, our data indicate that the presence
of anti-histone antibodies is classified as one of the
serologic abnormalities observed in polymyositis/
dermatomyositis. Keywords: enzyme-linked immuno-
sorbent assay/immunoblotting/humoral immunity. J Invest
Dermatol 112:711–715, 1999
and the patients with anti-PL-12 or anti-OJ antibodies tended to
show polyarthritis and Raynaud’s phenomenon (Maddison, 1996).
Anti-signal recognition particle antibodies, which are correlated
with severe myositis resistant to corticosteroid treatments (Targoff
et al, 1990), were also reported to be more prevalent in PM than
in DM (Mirande, 1991). Anti-Mi-2 antibodies, which are antibodies
to the Mi-2 protein complex (55 kDa and 235 kDa) with unknown
functions (Targoff and Reichlin, 1985), were reported to be DM-
specific and scarcely found in the patients with PM. Anti-Ku
antibodies that are prevalent in Japanese patients with systemic
sclerosis (SSc)–PM overlapping syndrome and anti-PM-Scl antibod-
ies that are prevalent in Caucasian patients are known (Mimori
et al, 1981; Reichlin et al, 1984). In addition, quite rare antibodies
including anti-KJ, anti-Fer, anti-Mas, anti-U1 ribonucleoprotein,
and anti-U2 ribonucleoprotein antibodies have been reported
(Targoff, 1993).
We recently experienced several patients with DM who showed
homogeneous stainings in indirect immunofluorescence studies,
and the homogeneous pattern cannot be explained by the antibodies
that have been previously revealed in DM. We, therefore, examined
the presence of anti-histone antibodies (AHA), which show homo-
geneous stainings in indirect immunofluorescence studies, in the
sera of patients with PM/DM.
AHA in collagen diseases were first reported by Kunkel et al
(1960) in the sera of the patients with systemic lupus erythematosus
(SLE), and subsequent studies revealed AHA in the sera from more
than 90% of the patients with drug-induced lupus erythematosus.
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Since then, the presence of AHA has been revealed in many kinds
of autoimmune diseases (Costa and Monier, 1986; Penner et al,
1987; Monestier et al, 1990; Sato et al, 1994). Furthermore, the
clinical correlations of AHA in SLE and SSc have been reported
(Gioud et al, 1982; Sato et al, 1994). The presence or prevalence
of AHA in PM/DM, however, has not been reported.
In this study, we determined the frequency and the antigen
specificity of AHA in the sera from patients with PM/DM by an
enzyme-linked immunosorbent assay (ELISA), an indirect immuno-
fluorescence study using HEp-2 cells and immunoblotting. We also
investigated the correlations between IgG AHA and clinical or
serologic features in patients with PM/DM.
MATERIALS AND METHODS
Patients and samples Serum samples were collected from 46 Japanese
patients with PM/DM (13 men and 33 women; age range, 13–68 y; mean
age 43 y). They were all the patients with PM/DM whose sera were
available and who had visited our clinic over the past 15 y. Two patients
with localized scleroderma and two patients with SLE were also included
as positive controls, whose sera had been reported previously as positive
for AHA (Sato et al, 1993).
The patients with PM/DM fulfilled the criteria of Bohan and Peter
(1975), and were classified into four subgroups: primary idiopathic poly-
myositis (three patients); primary idiopathic dermatomyositis (31 patients);
dermatomyositis associated with neoplasia (five patients); and juvenile
dermatomyositis (seven patients), according to the classification by Bohan
and Peter (1975). An electromyography, skin biopsy, and muscle biopsy
were performed at the time of diagnosis in all patients. Patients who had
other overlapping autoimmune diseases were excluded from this study.
Furthermore, no patients were treated with drugs that could induce
lupus-like syndromes, such as procainamide and hydralazine during the
disease course.
Control serum samples were obtained from 36 healthy volunteers (15
men and 21 women; age range 22–60 y; mean 38 y). All serum samples
were stored at –80°C prior to use.
The ELISA for AHA The ELISA was performed as described previously,
with some modifications (Gohill et al, 1985; Sato et al, 1993). Briefly,
microtiter plates (Corning, Corning, NY) were coated with 5 µg total
histones (Sigma, St. Louis, MO) per ml. The wells were then blocked
with phosphate-buffered saline (PBS) containing 10% fetal bovine serum
(PBS–FBS), and serum samples diluted to 1:400 in PBS–FBS were
added to each well. The bound antibodies were detected with alkaline
phosphatase-conjugated goat antihuman IgG or IgM antibodies (Cappel,
Durham, NC), using 10 mg p-nitrophenyl phosphate (Gibco BRL,
Gaithersburg, MD) per ml in 10% diethanolamine and 0.5 mM MgCl2
(pH 9.8) as substrate.
The plates were read at 405 nm in a Microplate Reader (Bio-Rad,
Hercules, CA). Absorption values greater than the mean plus 2 SD values
in the normal control sera were considered positive.
Indirect immunofluorescence study ANA was detected by indirect
immunofluorescence on HEp-2 cells as a substrate, as described previously
(Takehara et al, 1983). Serum samples diluted 1:400 in PBS were used for
the analysis of ANA.
Absorption test in immunofluorescent study Serum samples diluted
1:400 with 3 mg total histones (Sigma)/PBS per ml were incubated for
2 h at room temperature. After centrifugation (12,000 3 g, 15 min, room
temperature), the supernatant was used for an indirect immunofluorescence
study for ANA as described above.
Immunoblotting Total histones (Sigma) were subjected to electrophor-
esis on 15%/25% gradient sodium dodecyl sulfate polyacrylamide slab
gels, according to the technique of Laemmli (1970). The proteins were
electrotransferred from the gels to nitrocellulose sheets for an immunoblot-
ting analysis, as described elsewhere (Towbin et al, 1979). The nitrocellulose
sheets were cut into strips and incubated overnight with serum samples
diluted 1:50. The strips were then incubated for 1.5 h with alkaline
phosphatase-conjugated goat antihuman IgG antibody (Cappel), and color
was developed with 5-bromo-4-chloro-3-indolyl phosphate (Sigma) and
nitroblue tetrazolium (Sigma).
Absorption test in immunoblotting The absorption test in the immu-
noblotting was performed as a slight modification of the immunoblotting
described above. The main modifications were as follows; serum samples
Figure 1. Levels of AHA in sera from patients with PM/DM
determined by ELISA. (A) IgG AHA; (B) IgM AHA. Optical density
(OD) values were determined by an ELISA. Horizontal lines show the
mean 1 2 SD value (cut-off for positive result) in normal control sera.
Closed circles indicate the sera that were also positive in immunoblotting
tests.
diluted 1:400 in 3 mg total histones (Sigma) per ml were incubated for
2 h at room temperature. After centrifugation (12,000 3 g, 15 min, room
temperature), the supernatant was concentrated and used for immunoblot-
ting as 1:50 dilution of original serum.
Detection of other autoantibodies Antibodies to anti-tRNA synthe-
tases, and anti-signal recognition particle antibodies are detected and defined
by RNA immunoprecipitation and 35S protein immunoprecipitation as
described previously (Kuwana et al, 1994). Anti-U1 ribonucleoprotein
antibody, anti-Sm antibody, anti-topoisomerase I antibody, anti-Ku anti-
body and anti-Mi-2 antibody were detected by double immunodiffusion
as described previously (Fujimoto et al, 1997).
Statistics The significance of differences was assessed by Student’s t-test
and Chi-squared test. Relationships between variables were evaluated by
linear regression analysis. p , 0.05 was considered significant.
RESULTS
The ELISA for AHA The ELISA revealed IgG AHA in seven
of the 46 sera (15%) from patients with PM/DM (Fig 1A). IgM
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Figure 2. Indirect immunofluorescence
analysis and absorption by histones.
Homogeneous nuclear staining is shown in
(a) and (c). After incubation of the sera with
total histones, the homogeneous nuclear
staining disappeared [(b) and (d),
respectively]. Scale bar: 50 µm.
AHA were found in two of the 46 sera (4%) from patients with
PM/DM (Fig 1B). Both IgG AHA and IgM AHA were detected
in one serum.
Indirect immunofluorescence studies In the immunofluo-
rescent analysis, all eight sera that were positive for AHA by an
ELISA showed a homogeneous pattern (Fig 2a, c). After incubation
of the sera with 3 mg total histones per ml, the majority of
homogeneous pattern of nuclear staining were markedly decreased,
leaving behind a trace of nuclear staining. (Fig 2b, d, respectively).
These findings suggested that AHA may have played the major part
in the homogeneous pattern in the indirect immunofluorescence
analysis of these patients. The cytoplasmic and discrete speckled
residual stainings after incubation with total histones may indicate
the coexistence of other autoantibodies that were hidden by the
prominent homogeneous immunofluorescence by AHA before
incubation with total histones.
Immunoblotting We examined immunoblotting using all of
the sera from the patients with PM/DM, which showed a positive
reaction in the ELISA. All seven sera positive for IgG AHA and
one of the two sera positive for IgM AHA reacted with several
fractions of histones (Fig 3). AHA in these patients were predomi-
nantly directed against histone H1. Anti-H2A antibody and anti-H3
antibody were found in two sera (Fig 3, lanes 3 and 4). Anti-H2B
antibody and anti-H4 antibody were found in three sera (Fig 3,
lanes 3–5). The serum of the patient with PM/DM, which was
positive for IgM AHA in immunoblotting, reacted with all of these
fractions (Fig 3, lane 11). The serum also showed the same pattern
of reaction in IgG (Fig 3, lane 3). After incubation with 3 mg total
histones per ml, the positive reactions of all the seven serum samples
that showed anti-histone activities in the immunoblotting (Fig 4,
lanes 2 and 4) disappeared completely (Fig 4, lanes 3 and 5,
respectively).
Detection of other antibodies There were two patients with
anti-Jo-1 antibodies, two with anti-EJ antibodies, one with anti-
PL-12 antibodies, one with anti-signal recognition particle anti-
bodies, four with anti-Ku antibodies, and one with anti-U1
ribonucleoprotein antibodies (Table I). There were no patients
with anti-Mi-2 antibodies, anti-PL-7 antibodies or anti-OJ antibod-
ies. The anti-histone antibodies were found in two patients with
anti-Ku antibodies.
Clinical correlations We examined the correlations between
IgG AHA and the clinical and laboratory findings of the patients
Figure 3. Immunoblotting of total histones with the sera from the
patients with PM/DM positive for IgG AHA and/or IgM by an
ELISA. Lane 1, Colloidal gold stain; lane 2, positive control (localized
scleroderma); lanes 3–9, IgG anti-histone antibodies in PM/DM patient
sera; lane 10, normal human serum (IgG); lane 11, IgM anti-histone
antibodies in the serum of one patient with PM/DM.
with PM/DM (Table I). In this series, no patients with IgG AHA
showed lung fibrosis or internal malignancy. There were, however,
no statistically significant differences between patients with or
without AHA in view of any clinical or laboratory findings
including lung fibrosis, internal malignancies nor coexistence of
other autoantibodies. This may be because of the small number of
the patients with each specific autoantibodies.
DISCUSSION
Histones are basic nuclear small proteins found in all eukaryotic
cells, and they consist of several fractions whose molecular weights
are 12–20 kDa. Nuclear histones are bound to deoxyribonucleic
acid (DNA) and form units called nucleosomes. Fractions of histones
are designated as H1, H2A, H2B, H3, and H4. H1 is located on
the outside of nucleosomes and binds linker DNA. Nucleosomes
are composed of octamers of H2A, H2B, H3, and H4. Among
H2A, H2B, H3, and H4, the outer portion consists of H2A and
H2B whereas the inner portion consists of H3 and H4 (Sperling
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Figure 4. Absorption test in immunoblotting. The reactions with
histones (lanes 2 and 4) disappeared when the sera were incubated with
total histones (lanes 3 and 5, respectively). Lane 1 shows the colloidal gold
stain of total histones.
Table I. Clinical and laboratory findings in the patients
with PM/DM (nJ46) with positive or negative serum
IgG AHA
Patients with IgG Patients without IgG
AHA (n57) AHA (n539)
Males/females 3/4 10/29
Age (years; mean 6SD) 40 6 19 44 6 14
No. (%) with proximal MW 7 (100%) 27 (69%)
Skin eruption 6 (86%) 37 (95%)
Heliotropic coloration 4 (57%) 18 (46%)
Gottron’s papules 3 (43%) 22 (56%)
Raynaud’s phenomenon 1 (14%) 5 (13%)
Joint involvement 4 (57%) 15 (38%)
Lung fibrosis 0 (0%) 12 (31%)
Internal malignancy 0 (0%) 5 (13%)
Positive ANA 6 (86%) 22 (56%)
Positive ACyA 4 (57%) 7 (18%)
Elevated CK 7 (100%) 28 (72%)
Anti-synthetase antibodies 0 (0%) 5 (13%)
Anti-Jo-1 antibodies 0 (0%) 2 (5%)
Anti-EJ antibodies 0 (0%) 2 (5%)
Anti-PL-12 antibodies 0 (0%) 1 (3%)
Anti-SRP antibodies 0 (0%) 1 (3%)
Anti-Ku antibodies 2 (29%) 1 (3%)
Anti-U1 RNP antibodies 0 (0%) 1 (3%)
ACyA, anti-cytoplasmic antibodies; AHA, anti-histone antibodies; ANA, anti-
nuclear antobodies; CK, creatinine kinase activity; MW, muscle weakness; SRP,
signal recognition particles.
and Wachtel, 1981; Burlingame et al, 1985). Thus, the epitopes of
H1 are most accessible in native chromatin, followed by those of
H2B, H3, H2A, and H4.
It has been reported that antibodies to both H1 and H2B have
been detected in SLE and that antibodies to H1 or histone (H2A–
H2B)–DNA complexes were dominantly detected in SSc (Hardin
and Thomas, 1983; Sato et al, 1994; Wallace, 1994). This study
disclosed the predominance of anti-H1 antibodies to other fractions,
although in several cases, the antibodies to other fractions were
also found. The patterns of the antigen specificity of AHA in the
sera from the patients with PM/DM are partially similar to the
patterns in the sera of the patients with SSc. Several hypotheses
have been proposed regarding the production of autoantibodies.
Based on experimental observations and on the nature of auto-
antigens, the autoimmune response may be antigen-driven and
may be directed toward various components of the subcellular
particles, consisting of different species of proteins or of proteins
in association with nucleic acids (Tan, 1982). In an antigen-driven
production of autoantibodies, the accessibility of epitopes would
be in proportion to the prevalence of the antibody to each fraction.
In our study, the prevalence of antibody to each fraction seemed
to be compatible with the accessibility of the epitopes of each
fraction, and these results may thus support the ‘‘antigen-driven’’
hypothesis. Furthermore, in this study, AHA were detected in two
patients with anti-Ku antibodies. The Ku antigen is protein complex
of DNA binding, thus, the coexistence of anti-Ku antibody and
anti-histone antibody may be due to the nearness of their epitopes.
In various other diseases including autoimmune diseases, the
existence of both IgG AHA and IgM AHA has been revealed
(Rubin et al, 1982; Krippner et al, 1984; Penner et al, 1987; Sato
et al, 1994). Only the IgG subclass of AHA was strongly found,
however, and the IgM subclass was disclosed only weakly in patients
with PM/DM in this ELISA study in comparison with other
diseases. Additionally, the prevalence of IgM AHA was much lower
than that of IgG AHA in the sera of patients with PM/DM. Gioud
et al (1982) previously reported that only IgG AHA were correlated
with clinical severity whereas IgM AHA were nonspecific and not
correlated with clinical appearances in SLE. The difference in the
prevalence of AHA between IgG and IgM may indicate the
superiority of IgG to IgM in clinical or laboratory findings also in
patients with PM/DM. In our case, only one of the two patients
with IgM AHA using ELISA was also shown to have IgM AHA
using immunoblotting. We think the fact that IgM AHA detected
in the other case by an ELISA was not detected using immunoblot-
ting is due to the different assay systems in ELISA and immunob-
lotting.
In this study, AHA were found in 17% of 46 patients with PM/
DM by ELISA. This prevalence of AHA in PM/DM was rather
smaller than that in SLE, SSc, and localized scleroderma (Costa
and Monier, 1986; Sato et al, 1993, 1994). The prevalence, however,
is quite similar to that prevalence of Jo-1 antibody in PM/DM,
and is rather greater than that of other autoantibodies in PM/DM
(Targoff, 1993).
Regarding the autoantibodies identified in PM/DM, several
clinical and laboratory studies based on antibody-oriented grouping
have been reported. No significant correlations between AHA and
clinical or laboratory findings in the patients with PM/DM were
found in this study, whereas the association of AHA with severity
of the disease had been reported in SSc and SLE (Konstantinov
et al, 1986; Kohda et al, 1989; Sato et al, 1994). In this study,
internal malignancies and lung fibrosis, which are the most severe
complications in PM/DM, were not found in the patients positive
for AHA, whereas the differences in the rate of complication of
these conditions were not statistically significant. In light of the
high prevalence of AHA in the patients with PM/DM, further
accumulations of patients may reveal correlations of AHA with
clinical or laboratory findings in patients with PM/DM.
In conclusion, AHA were found in 17% of 46 patients with
PM/DM by anELISA. The prevalence was rather larger than that
of other autoantibodies previously found in PM/DM, and the
VOL. 112, NO. 5 MAY 1999 ANTI-HISTONE ANTIBODIES IN POLYMYOSITIS/DERMATOMYOSITIS 715
predominant subclass of AHA observed was IgG. The AHA played
the major part in the homogeneous appearance in the indirect
immunofluorescence study in these patients. The antigenicity was
mostly against the fraction of histone H1, followed by H2A, H2B,
H3, and H4. Although the clinical and laboratory data of the
patients whose sera were positive for AHA showed no correlation
with AHA in the statistical analysis, further accumulations of
patients may reveal some relationship between AHA and the clinical
or laboratory findings of patients with PM/DM, in part because
none of the present patients with AHA had lung fibrosis or internal
malignancies.
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